Methamphetamine motivated murder: Forensic psychological/psychiatric & legal applications in criminal contexts

Journal of Psychiatry and Law

Volumn 35, Issue 4, 2007, Pages 443-474

  Fabian, John Matthew ^a  

^a CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

Forensic psychiatry; Forensic psychology; Insanity; Methamphetamine; Mitigation; Substance induced psychosis

Indexed keywords

METHAMPHETAMINE;

ADDICTION; CRIME; CRIMINAL LAW; DRUG ABUSE; DRUG EFFECT; FORENSIC PSYCHIATRY; GUILT; HEALTH PRACTITIONER; HOMICIDE; HUMAN; LEGAL ASPECT; MENTAL DISEASE; MENTAL HEALTH; PSYCHOSIS; REVIEW; VIOLENCE;

EID: 44649100164     PISSN: 00931853     EISSN: None     Source Type: Journal    
DOI: 10.1177/009318530703500403     Document Type: Review

References (91)

1. American Psychiatric Association (APA) (2000). Diagnostic and Statistical Manual, 4th Ed., Text Revision. Washington, DC.
2. Am. Jur. 2d Criminal law §155.
3. Ando, K., Hironaka, N. & Yanagita, T. (1986). Psychotic manifestations in amphetamine abuse-experimental study on the mechanism of psychotic recurrence. Psychopharmacological Bulletin, 22(3), 763-767.
4. Anglin, M., Burke, C., Perrochet, B., Stamper, E. & Dawud-Noursi, S. (2000). History of the methamphetamine problem. Journal of Psychoactive Drugs, 32(2), 137-141.
5. Barnett, M.E., Brodsky, S.L. & Davis, C.M. (2004). When mitigation evidence makes a difference: Effects of psychological mitigating evidence on sentencing decision in capital trials. Behavioral Sciences and the Law, 22(6), 751-770.
6. Barnett, M.E., Brodsky, S.L. & Price, R.J. (2007). Differential Impact of Mitigating Evidence in Capital Case Sentencing. Journal of Forensic Psychology Practice, 7(1), 39-45.
7. Batki, S. & Harris, D. (2004). Quantitative drug levels in stimulant psychosis: Relationship to symptom severity, catecholamines and hyperkinesias. American Journal of Addictions, 13(5), 461-470.
8. Bennett, B., Hollingsworth, C., Martin, R. & Harp, J. (1998). Methamphetamine-induced alterations in dopamine transporter function. Brain Research, 782(1-2), 219-227.
9. Bieber vs. People, 856 P. 2d 811 (1993).
10. Boles, S. & Miotto, K. (2003). Substance abuse and violence. A review of the literature. Aggression and Violent Behavior, 8, 155-174.
11. Buffenstein, A., Coel, M. & Combs, B. (1997). Functional Neuroimaging of Chronic Crystal Methamphetamine Users. Unpublished grant application, University of Hawaii, John A. Burns School of Medicine.
12. Burns, K. & Bechara, A. (2007). Decision Making and Free Will: A Neuroscience Perspective. Behavioral Sciences and the Law, 25, 263-280.
13. Caton, C.L., Samet, S. & Hasin, D.S. (2000). When acute-stage psychosis and substance co-occur: Differentiating substance-induced and primary psychotic disorders. Journal of Psychiatric Practice, 6(5), 256-266.
14. Carter-Yamauchi, C. (1998). Drugs, Alcohol And The Insanity Defense: The Debate Over "Settled" Insanity. Legislative Reference Bureau.
15. Cartier, J., Farabee, D. & Prendergast, M. (2006). Methamphetamine use, self-reported violent crime, and Recidivism among offenders in California who abuse substances. Journal of interpersonal violence (21)4, 435-445.
16. Commonwealth vs. Davenport, 494 Pa 532, 431 A. 2d 982 (1981).
17. Commonwealth vs. Tate, 893 S.W. 2d 368 (Ky. 1995).
18. Crocker, P. (1997). Deathworthiness, Differentiating Between Guilt and Punishment in Death Penalty Cases. 66 Fordham Law Review, 21.
19. Eddings vs. Oklahoma, 455 U.S. 104 (1982).
20. Ernst, T., Chang, L., Leonido-Yee, M. & Speck, O. (2000). Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology, 54(6), 1344-1349.
21. Fischman, M. & Haney, M. (1999). Neurobiology of stimulants. In Galanter, M. & Kleber, H.D. (Eds.), Textbook of substance abuse treatment, 2nd ed., pp. 21-31. Washington, DC: American Psychiatric Press.
22. Gabbard, G.O. (1995). Treatment of Psychiatric Disorders, 2nd ed. Vol. 1, pp. 708-720, American Psychiatric Press, Washington, DC.
23. Griffith, J.D., Cavanaugh, J. & Oats, J. (1969). Schizophrenic psychosis induced by large dose administration of diamphetaime. Journal of Psychadelic Drugs, 2, 42-48.
24. Hall, H., McPherson, S., Twemlow, S. & Yudko, E. (2003). Boca Raton, FL: CRC Press.
25. Hartel-Petri, R., Rodler, R., Schmeisser, U., Steinmann, J. & Wolfersdorf, M. (2005). Increasing prevalence of amphetamine- and methamphetamine-induced psychosis. Psychiatric Practice, 32(1), 13-17.
26. Hassman, P.E. (1977). Drug Addiction or Related Mental State as Defense to Criminal Charge, 73 A.L.R.3d 16.
27. Hunt, D., Kuck, S. & Truitt, L. (2005). Methamphetamine Use: Lessons Learned. Analytic Support Program Contract. Cambridge, MA: Abt Associates Inc.
28. Iyo, M., Nishio, M., Itoh, T., Fukuda, H., Suzuki, K., Yamasaki, T., Fukui, S. & Tateno Y. (1993). Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography. Psychiatry Research, 50(4), 217-231.
29. Iyo, M., Sekine, Y. & Mori, N. (2004). Neuromechanism of developing methamphetamine psychosis: A neuroimaging study. Annals New York Academy of Science, 1025, 288-295.
30. Jellinek, E. (1960). The Disease Concept of Alcoholism. New Haven, CT: College & University Press.
31. Kaplan, H. & Sadock, B. (1998). Kaplan & Sadock's Synopsis of Psychiatry Behavioral Sciences/Clinical Psychiatry 8th ed. Philadelphia, PA: Lippincott, Williams & Wilkins.
32. Kobayashi, H., Ide, S., Hasegawa, J., Ujike, H., Sekine, Y., Ozaki, N., Inada, T., Harano, M., Komiyama, T., Yamada, M., Iyo, M., Shen, H., Ikeda, K. & Sora, I. (2004). Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence. Annals of New York Academy of Science, 1025, 325-334.
33. Kosten, T. & Singha, A. (1999). Stimulants. In Galanter, M., Kleber, H.D. (Eds.). Textbook of substance abuse treatment, 2nd ed., pp. 183-193. Washington, DC: American Psychiatric Press.
34. Lin, S., Ball, D., Hsiao, C., Chiang, Y., Ree, S. & Chen, C. (2004). Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan. Psychiatry Clinical Neuroscience, 58(2), 206-212.
35. Lockett vs. Ohio, 438 U.S. 586 (1978).
36. London, E.D., Simon, S.L., Berman, S.M., Mandelkern, M.A., Lichman, A.M., Bramen, J., Shinn, A.K., Miotto, K., Learn, J., Dong, Y., Matochik, J.A., Varughese, K., Newton, T., Woods, R., Rawson, R. & Ling, W. (2004). Mood Disturbances and Regional Cerebral Metabolic Abnormalities in Recently Abstinent Methamphetamine Abusers. Archives of General Psychiatry, 61(1).
37. MacKenzie, R. & Heischober, B. (1997). Methamphetamine. Pediatric Review, 18(9), 305-309.
38. Marlowe, D.B., Lambert, J.B. & Thompson, R.G. (1999). Voluntary Intoxication and Criminal Responsibility. Behavioral Sciences and the Law, 17, 195-217.
39. Miczek, K. & Tidey, J. (1989). Amphetamines: Aggressive and social behavior. NIDA Research Monograph, 94, 68-100.
40. Model Penal Code 4.01(1) (Official Draft 1962).
41. Monahan, J., Steadman, H.J., Silver, E., Applebaum, P.S., Robbins, P.C., Mulvey, E.P., Roth, L., Grisso, T. & Banks, S. (2001). Rethinking risk assessment: The MacArthur study of mental disorder and violence. New York: Oxford University Press.
42. Montana vs. Egelhoff, 518 U.S. 37 (1997).
43. Murray, J.B. (1998). Psychophysiological aspects of amphetamine- methamphetamine abuse. Journal of Psychology, 132(2), 227-237.
44. National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1990). Alcohol and health: Seventh special report to Congress. Rockville, MD:Author.
45. National Instiute on Drug Abuse (1998). Methamphetamine abuse alert. NIDA Notes, 13(6).
46. Ohgake, S., Hashimoto, K., Shimizu, E., Koizumi, H., Okamura, N., Koike, K., Matsuzawa, D., Sekine, Y., Inada, T., Ozaki, N., Iwata, N., Harano, M., Komiyama, T., Yamada, M., Sora, I., Ujike, H., Shirayama, Y. & Iyo, M. (2005). Functional polymorphism of the NQO2 gene is associated with Methamphetamine psychosis. Addiction Biology, 10(2), 145-148.
47. Ohio Revised Code O.R.C. 2929.04 (B).
48. People vs. Free, 447 N.E. 2d 218 (1983).
49. People vs. Kelly, 10 Cal. 3d 565, 516 P.2d 875 (1973).
50. People vs. McCarthy, 110 Cal. App. 3d 296 (1980).
51. People vs. Skinner, 39 Cal. 3d 765 (1985).
52. Perez-Reyes, M., White, W., McDonald, S., Hicks, R., Jeffcoat, Hill, J. & Cook, C. (1991). Clinical effects of daily methamphetamine administration. Clinical Neuropharmacology, 14, 352-358.
53. Porreca vs. State, 49 Md. App. 522, 433 A.2d 1204 (1981).
54. Pranther vs. Commonwealth, 215 Ky. 714 (1926).
55. th ed. New York, NY: McGraw-Hill.
56. Reiss, A., & Roth, J. (1993). Alcohol, other psychoactive drugs and violence. In Reiss, A.J. & Roth, J.A. (Eds.), Understanding and preventing violence (pp. 182-220). Washington, DC: National Academy Press.
57. Roth, J. (1994). Psychoactive substance and violence. Washington, DC: National Institute of Justice, Office of Justice Programs (February).
58. Sato, M., Chen, C.C., Akiyama, K. & Otsuki, S. (1983). Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Journal of Biological Psychiatry, 18(4): 429-440.
59. Sato M. (1992). A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Annals New York Academy of Science, 28: 160-170.
60. Sato, M., Numach,i Y. & Hamamura, T. (1992). Relapse of paranoid psychotic state in methamphetamine model of Schizophrenia. Schizophrenia Bulletin, 18(1): 115-122.
61. Sekine, Y., Minabe, Y., Kawai, M., Suzuki, K., Iyo, M., Isoda, H., Sakahara, H., Ashby, C., Takei, N. & Mori, N. (2002). Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRA study. Neuropsychopharmacology, 27(30): 453-461.
62. Srisurapanont, M., Ali, R., Marsden, J., Sunga, A., Wada, K. & Monteiro, M. (2003). Psychotic symptoms in m psychotic inpatients. International Journal of Neuropsychopharmacology, 6(4), 347-352.
63. State vs. Baldwin, 330 N.C. 446 (1992).
64. State vs. Harden, 260 Kan. 365 (1971).
65. State vs. Hartfield, 300 S.C. 469, 388 S.E. 2d 802 (1989).
66. State vs. Hartfield, 300 S.C. 469; 388 S.E. 2d 802 (1990).
67. State vs. Keeton, 166 W.Va. 77, 272 S.E. 2d 817 (1980).
68. State vs. Maik, 287 A. 2d 715 (1972).
69. State vs. Scales, N.C. App. 509 (1976).
70. State vs. Shank, 322 N.C. 243 (1988).
71. State vs. Silvers, 323 N.C. 646 (1989).
72. Subcommittee on Crime of the Committee of the Judiciary, House of Representatives, 104th Congress, First Session, October 26, 1995 (Ser. No. 49), Rising Scourge of Methamphetamine in America.
73. Swanson, J.W. (1994). Mental disorder, substance abuse, and community violence: An epidemiological approach. In Monahan, J. & Steadman, H.J. (Eds.), Violence and Mental Disorder: Developments in Risk Assessment (pp. 101-136). Chicago, IL: University of Chicago Press.
74. Thompson, P.M., Hayashi, K.M., Simon, S.L., Geaga, J.A., Hong, M.S., Sui, Y., Lee, J.Y., Toga, A.W., Ling, W. & London, E.D. (2004). Structural Abnormalities in the Brains of Human Subjects Who Use Methamphetamine. The Journal of Neuroscience, 24(26), 6028-6036.
75. Ujike, H., Harano, M., Inada, T., Yamada, M., Komiyama, T., Sekine, Y., Sora, I., Iyo, M., Katsu, T., Nomura, A., Nakata, K. & Ozaki, N. (2003). Nine-or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged m psychosis. Pharmacogenomics Journal, 3(4), 242-247.
76. United States Drug Enforcement Agency. Retrieved March 18, 2007 from http://www.usdoj.gov/dea/pubs/
77. United States vs. Burnium, 576 F. 2d 236 (1978).
78. United States vs. Garcia, 94 F. 3d 57 (1996).
79. United States vs. Knott, 894 F. 2d 1119 (1990).
80. U.S. vs. Lyons, 731 F.2d 243 (5th Cir. 1984).
81. Watson vs. United States, 141 App. D.C. 335 (1970).
82. Wolkoff, D.A. (1997). Methamphetamine abuse: an overview for health care professionals. Journal of Medicine, 56(2): 34-6, 44.
83. Woodson vs. North Carolina, 428 U.S. 280 (1976).
84. Yeh, H., Lee, Y., Sun, H. & Wan, S. (2001). Six months follow-up of patients with methamphetamine psychosis. Zhonghua Yi Xue Za Zhi (Taipei), 64(7), 388-394.
85. Yudko, E., Hall, H., McPherson, S. & Twemlow, S. (2003). Physiology. In Yudko, E., Hall, H. & McPherson, S. Eds. Methamphetamine Use Clinical and Forensic Aspects. Boca Raton, FL: CRC Press.
86. Yudko, E., Murray-Bridges, S. & Watson-Hauanio, S. (2003). History of Methamphetamine. In Yudko, E., Hall, H. & McPherson, S. Eds. Methamphetamine Use Clinical and Forensic Aspects. Boca Raton, FL: CRC Press.
87. Yui, K., Goto, K., Ikemoto, S., Nishijima, K., Yoshino, T. & Ishiguro, T. (2001). Susceptibility to subsequent episodes of spontaneous recurrence of m psychosis. Drug Alcohol Dependence, 64(2), 133-142.
88. Yui K., Goto K., Ikemoto, S. & Ishiguro, T. (1997). Methamphetamine psychosis: Spontaneous Recurrence of paranoid-hallucinatory states and monoamine neurotransmitter function. Journal of Clinical Psychopharmacology, 17(1): 34-43.
89. Yui, K., Goto, K. & Ikemoto, S. (2004). The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence. Annals of New York Academy of Science, 1025, 296-306.
90. Yui, K., Ikemoto, S. & Goto, K. (2002). Factors for susceptibility to episode recurrence in spontaneous recurrence of m psychosis. Annals of New York Academy of Science, 965, 292-304.
91. Yui, K., Ikemoto, S., Goto, K., Nishijima, K. & Kato, S. (2003). Susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis. Journal of Clinical Psychopharmacology, 23(5), 525-528.